Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06832306 · ClinicalTrials.gov registry record · NA
STimulation to Activate RespIration
A NA study of ARDS (Moderate or Severe) and AHRF, sponsored by Lungpacer Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT06832306: Recruiting NA study of ARDS (Moderate or Severe) and AHRF, sponsored by Lungpacer Medical.
NCT06832306 is a NA study of ARDS (Moderate or Severe) and AHRF that is actively recruiting participants, run by Lungpacer Medical. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06832306, a NA study of ARDS (Moderate or Severe) and AHRF, is actively recruiting participants, sponsored by Lungpacer Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
Multi-center, randomized, controlled, open-label Phase 2 feasibility trial. Subjects on mechanical ventilation (MV) for acute hypoxemic respiratory failure (AHRF) with lung injury (including subjects who meet criteria for acute respiratory distress syndrome (ARDS)) will be randomized 2:1 to diaphragm neurostimulation-assisted ventilation (DNAV) using the AeroNova System plus lung-protective ventilation (Treatment) vs. lung-protective ventilation alone (Control).
Conditions Studied
Interventions
- DEVICE Phrenic Nerve Stimulation
Study Locations (6)
California
- University of California San Diego - La Jolla
Louisiana
- Louisiana State University Health Sciences - Shreveport
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- Temple University - Philadelphia
South Carolina
- Prisma Health - Columbia
Ontario
- University Health Network (UHN) - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-05-28 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT06832306 shows while recruiting
NCT06832306 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with ARDS (Moderate or Severe) appearing as the primary indexed condition, and to 1 intervention - of which Phrenic Nerve Stimulation is the first listed.
NCT06832306 lists 6 locations in 6 states (California, Louisiana, Ohio).
Frequently Asked Questions
What is clinical trial NCT06832306 about?
NCT06832306 is a clinical study titled "STimulation to Activate RespIration". Multi-center, randomized, controlled, open-label Phase 2 feasibility trial. Subjects on mechanical ventilation (MV) for acute hypoxemic respiratory failure (AHRF) with lung injury (including subjects who meet criteria for acute respiratory distress syndrome (ARDS)) will be randomized 2:1 to diaphrag...
What is the current status of trial NCT06832306?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-05-28. Estimated completion is 2026-12.
What conditions does trial NCT06832306 study?
This clinical trial studies the following conditions: ARDS (Moderate or Severe), AHRF, Mechanically Ventilated ICU Patients.
What interventions are being tested in trial NCT06832306?
The interventions under investigation include: Phrenic Nerve Stimulation (DEVICE).
Who is sponsoring clinical trial NCT06832306?
This trial is sponsored by Lungpacer Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06832306 being conducted?
This trial has 6 study locations across California, Louisiana, Ohio, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06832306's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI